[Edaily Reporter Kwon Oh-seok] #InBody shares are surging in early trading. Buying interest appears to be surging on news that the company is partnering with a global Big Pharma firm to target the Chinese GLP-1 obesity treatment market.

According to MP Doctor on the 10th, InBody shares were trading at 44,800 won as of 9:50 a.m., up 8.35% from the previous trading day.
Earlier today, InBody’s Chinese subsidiary announced, “We have been selected as a key partner for the ‘In-Pharmacy Weight Management Room’ project, which will be rolled out nationwide using a pharmacy franchise network in China in partnership with a global big pharma company.”
The strategy is to establish itself in China—considered the next battleground in the global GLP-1 market—as a "medical weight management infrastructure" that goes beyond simple weight loss to minimize muscle loss. InBody is leading the creation of a chronic disease management ecosystem, ranging from equipment supply to specialized training and installation.
Through this collaboration, InBody’s Chinese subsidiary has begun supplying the professional body composition analyzer “InBody 260S” to major pharmacy franchises across China. Additional supplies are scheduled to follow sequentially.
A company representative stated, “Building on this successful collaboration with a global pharmaceutical company, we will expand our partnerships with pharmaceutical ecosystems and medical institutions worldwide to help patients safely recover their health while minimizing muscle loss.”